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Nesiritide is recombinant B-type natriuretic peptide (BNP)1–4 approved for use in patients with acute heart 
failure, because of its ability to reduce pulmonary-capillary 
wedge pressure and improve dyspnea.3,5 Yet after approval, it 
was suggested that nesiritide might cause renal toxicity and 
increase mortality. Specifically, in a meta-analysis of 5 ran-
domized studies with 1269 acute heart failure patients com-
pared with placebo, intravenous nesiritide increased the rate 
of worsening renal function by 50%, although confidence 
intervals around this estimate were wide.6,7 These concerns led 
to a marked decrease in the use of nesiritide.8
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The Acute Study of Clinical Effectiveness of Nesiritide and 
Decompensated Heart Failure (ASCEND-HF) was conducted 
to re-evaluate the efficacy and safety of nesiritide, com-
pared with placebo, added to standard of care in 7141 acute 
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was defined as an increase of serum creatinine >0.3 mg/dL and a change of ≥25%. Median (25th–75th percentile) baseline 
creatinine was 1.2 (1.0–1.6) mg/dL and median baseline blood urea nitrogen was 25 (18–39) mmol/L. Changes in both 
serum creatinine and blood urea nitrogen were similar in nesiritide-treated and placebo-treated patients (P=0.20 and 
P=0.41) from baseline to discharge. In a multivariable model, independent predictors of change from randomization to 
hospital discharge in serum creatinine were a lower baseline blood urea nitrogen, higher systolic blood pressure, lower 
diastolic blood pressure, previous weight gain, and lower baseline potassium (all P<0.0001). The frequency of worsening 
renal function during hospitalization was similar in the nesiritide and placebo group (14.1% and 12.8%, respectively; 
odds ratio with nesiritide 1.12; confidence interval, 0.95–1.32; P=0.19) and was not associated with death alone and death 
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decompensated heart failure (ADHF) patients. Overall, com-
pared with placebo, nesiritide did not improve (or worsen) 
clinical outcomes and nesiritide did not increase the risk of 
worsening renal function (predefined as >25% decrease in 
estimated glomerular filtration rate).9
Our study was a retrospective analysis of ASCEND-HF, in 
which we examined the detailed effects of nesiritide on renal 
function, clinical predictors of changes in creatinine, and the 
relationship between changes in renal function and outcomes.
Methods
ASCEND-HF was a randomized, double blind, placebo-controlled 
trial of nesiritide in addition to standard of care.10 The trial was con-
ducted from May 2007 through August 2010 at 398 international cen-
ters. Patients were included if they were hospitalized for heart failure 
occurring within 24 hours before they received their first intravenous 
treatment for heart failure, or if they had received a diagnosis of ADHF 
<48 hours after hospitalization for another cause, and underwent ran-
domization within 24 hours after intravenous treatment. Patients were 
excluded if they had a high risk of hypotension (systolic pressure <100 
mm Hg or 110 mm Hg with the use of intravenous nitroglycerin), other 
contraindications for vasodilators, persistent uncontrolled hypertension, 
normal levels of BNP or N-terminal proBNP (NT-proBNP), chronic or 
intermittent renal support therapy (ie, hemodialysis, ultrafiltration, or 
peritoneal dialysis), or clinically significant anaemia.10 Eligible patients 
were randomly assigned in a 1:1 ratio to receive nesiritide or placebo, 
in addition to standard therapy. After a recommended (but optional) 
intravenous bolus of nesiritide, at a dose of 2 μg per kilogram, nesirit-
ide was administered as a continuous infusion of 0.010 μg per kilogram 
per minute for 24 hours or more, for up to 7 days.
The ASCEND-HF study was approved by each participating 
center’s ethics committee or institutional review board, and all par-
ticipants provided written informed consent (ClinicalTrials.gov #: 
NCT00475852).
Patients for Analyses
A total of 7141 patients underwent randomization; of these, 7007 
(98%) received the study drug and were included in the modified 
intention-to-treat analysis. The study groups were well-balanced and 
similar to the intention-to-treat group.9 Our retrospective analysis 
of ASCEND-HF focuses on the 5702 patients who had both base-
line and inpatient peak creatinine measurement available for review 
(Table I in the online-only Data Supplement).
Worsening Renal Function
Worsening renal function was defined as an increase of serum creati-
nine >0.3 g/dL (26.5 μmol/L) and ≥25% change.11,12 Creatinine was 
measured at baseline and at discharge.
End Points
The primary end point of interest in this study is the composite of 
rehospitalization for heart failure and death from any cause within 
30 days postevent. The other end point of interest was the separate 
outcome of rehospitalization for heart failure or death from any cause 
within 30 days. The following criteria were required for hospitaliza-
tion events to be classified as attributable to heart failure: typical clin-
ical manifestations of worsening heart failure and the addition of (or 
increase in) treatment specifically for worsening heart failure with an 
intravenous pharmacological agent, or mechanical or surgical inter-
vention or ultrafiltration, hemofiltration, or dialysis specifically for 
the management of persistent or worsening heart failure.
Statistical Analyses
Change in creatinine was defined as the change from baseline to 
peak during hospitalization (Table 1, which displays 2 groups, those 
changes ≤0.3 mg/dL and those >0.3 mg/dL).13,14 Presenting factors, 
baseline medications, and medical history information is reported as 
counts and frequencies for discrete factors and either the mean with 
standard deviation or 50th, 25th, and 75th percentiles for continuous. A 
Wilcoxon rank-sum test was performed for continuous factors, and a 
χ2 test was performed for binary measurements.
Cox proportional hazards regression modeling was generated 
to assess the association between prespecified baseline factors and 
change in creatinine (from randomization to discharge). To verify 
modeling assumptions, plots were generated to view the residuals 
of each independent predictor. Outliers of creatinine measurements 
≥10 mg/dL were excluded. The blood urea nitrogen (BUN), BNP, 
and NT-proBNP were modeled using log transformations. A test for 
normality was evaluated. The stepwise variable selection procedure 
was applied using a P value of 0.05 for to enter and stay in the model. 
Interactions between treatment and baseline factors were reviewed.
Analyses on the prognostic value of serum creatinine were sepa-
rated into 2 cohorts. The first and most valuable cohort consisted of 
all patients having baseline values of serum creatinine as well as one 
or more other serum creatinine values. Of all serum creatinine val-
ues during hospitalization, the highest value was taken as peak serum 
creatinine value. Change in creatinine values was calculated as peak 
value minus baseline value. The second smaller cohort consisted of 
patients having baseline and discharge values of creatinine, ignoring 
other serum creatinine values during hospitalization.
Baseline, discharge, peak, and change from baseline to each cre-
atinine measurement were modeled univariably as predictors of 
30-day mortality and 30-day mortality or rehospitalization for heart 
failure. These same measurements were also added to previously 
generated multivariable models for 30-day mortality and 30-day 
mortality or rehospitalization for heart failure. The 30-day mortal-
ity model includes age, sodium, systolic blood pressure, dyspnea, 
BNP, and NT-proBNP. The combination end point of 30-day mor-
tality and rehospitalization includes age, cerebrovascular disease, 
chronic respiratory disease, depression, hospitalization within the 
past year, sodium, qualifying jugular venous pressure episode, sys-
tolic blood pressure, weight, BNP, and NT-proBNP. Each creatinine 
term was added individually to assess the measurement’s importance 
after adjusting for these baseline characteristics. The baseline, peak, 
and discharge measurements were modeled using the log transfor-
mation. The log of creatinine is also analyzed using each measure 
in a time-dependent covariate analysis unadjusted and adjusted for 
the prespecified baseline confounders. This time-dependent analysis 
provided updated assessments of creatinine measures over time. The 
time-dependent variable is initially set to the baseline measure. As 
follow-up time matches the date that a new creatinine measurement 
is observed, the time-dependent variable is changed to the updated 
value. Creatinine and BUN measurements are displayed at different 
time points in Figure 1. The cumulative distribution of creatinine 
measurements by treatment at the end of treatment and discharge are 
displayed in Figure 2. Kaplan–Meier plots were generated to display 
the relationship of worsening renal failure and 30-day mortality.
SAS version 9.2 (SAS Institute, Cary, NC) was used for all 
analyses.
Results
Baseline characteristics (as presented in Table 1) of the 5702 
patients who were included in the present study did not clini-
cally differ from the 1439 patients who were excluded because 
of missing creatinine data (data not shown). Patients who 
were excluded were 66.3±14.6 years old (versus 65.3±14.0, 
P=0.002 for the included patients), 33% were female (versus 
34%, P=0.437), and had similar systolic and diastolic blood 
pressures (122 versus 123 mm Hg [P=0.198] and 73 ver-
sus 75 mm Hg [P=0.001], respectively). Although excluded 
patients had modestly higher baseline weight (80 versus 77 
kg, P<0.001) they had a similar drop in weight during hospi-
talization (−2.2 versus −2.3 kg, P=0.829). Excluded patients 
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Table 1.  Clinical Characteristics (Split by >0.3 mg/dL Change in Creatinine [Peak From Baseline])
Total
WRF status
P ValueNo Yes
Number of patients 5702 4041 1661
Nesiritide*† 2871 (50%) 1974 (49%) 897 (54%) <0.001
Placebo 2831 (50%) 2067 (51%) 764 (46%)
Age, y (SD) † 65.3 (14.0) 64.3 (14.2) 67.6 (13.3) <0.001
Female sex† 1964 (34%) 1319 (33%) 645 (39%) <0.001
Median weight, kg 77 (64, 94) 76 (62, 92) 82 (68, 99) <0.001
Median SBP† 123 (110, 140) 120 (110, 137) 130 (114, 145) <0.001
Median DBP† 75 (67, 84) 75 (68, 83) 75 (65, 84) 0.517
Median heart rate† 82 (72, 96) 84 (72, 96) 80 (70, 93) <0.001
Race† <0.001
 White 3090 (54%) 2070 (51%) 1020 (61%)
 Black 863 (15%) 570 (14%) 293 (18%)
 Asian 1512 (26%) 1244 (31%) 268 (16%)
 Other 236 (4%) 156 (4%) 80 (5%)
Medical history
 HF-PEF 15.2% 12.8% 21.1% <0.001
 Myocardial infarction† 34.4% 33.8% 35.9% 0.122
 Atrial fibrillation 36.7% 34.9% 41.0% <0.001
 Hypertension 71.6% 68.3% 79.7% <0.001
 Diabetes mellitus† 41.8% 39.5% 47.3% <0.001
 Loop diuretic in first 24h† 89.2% 88.9% 90.2% 0.145
Medication use (prerandomization)
 ACEI/ARB 60.9% 60.4% 62.2% 0.201
 Aldosteron antagonist 28.0% 29.1% 25.3% 0.004
 Beta blockers 56.5% 54.8% 60.8% <0.001
 Loop diuretics 62.2% 60.9% 65.4% 0.001
 Oral/topical nitrates 23.0% 21.6% 26.2% <0.001
 Digoxin 26.4% 27.5% 23.8% 0.005
 Hydrazaline 6.4% 4.7% 10.6% <0.001
 Anticoagulant 22.6% 21.4% 25.6% 0.001
 Inotropes 4.4% 5.2% 2.4% <0.001
 Vasodilators 15.7% 15.7% 15.9% 0.847
Baseline laboratory
 eGFR (mL/min/m2) 62±25 63±24 59±27 <0.001
 Creatinine (mg/dL) † 1.2 (1.0, 1.5) 1.2 (1.0, 1.5) 1.3 (1.0, 1.6) <0.001
 BUN (mmol/L)† 25 (18, 38) 25 (18, 38) 26 (18, 39) 0.113
 Hemoglobin (g/dL)‡ 12.7 (11.4, 14.1) 12.8 (11.5, 14.1) 12.5 (11.1, 13.9) <0.001
 BNP (pg/mL)† 990 (539, 1865) 1010 (538, 1943) 928 (542, 1696) 0.076
 NT-proBNP (pg/dL) 4357 (2019, 9082) 4240 (2002, 8955) 4642 (2094, 9550) 0.075
 Sodium† 139 (136, 141) 138 (136, 141) 139 (137, 142) <0.001
 Potassium† 4.1 (3.7, 4.5) 4.1 (3.7, 4.4) 4.1 (3.7, 4.5) 0.316
 Median LVEF 30 (20–36) 28 (20, 35) 30 (24, 40) <0.001
 Median change in SBP −8 (−20, 3) −7 (−20, 4) −10 (−25, 1) <0.001
 Median change weight† −2.3 (−5.0, −0.6) −2.1 (−4.8, −0.6) −2.7 (−5.3, −0.6) 0.034
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, b-type natriuretic peptide; BUN, blood urea nitrogen; DBP, diastolic blood 
pressure; eGFR, estimated glomerular filtration rate; h, hour; HF-PEF, heart failure–preserved ejection fraction; kg, kilograms LVEF, left ventricular ejection fraction; NT, N-terminal; 
NT-proBNP, N-terminal probrain natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; SD, standard deviation; and WRF, worsening renal function.
*There was no difference between nesiritide and placebo in quintiles of change in creatinine
†All prespecified factors included in the stepwise model of Table 2, including respiration rate, orthopnea, dyspnea, peripheral edema, pulmonary congestion on x-ray, 
paroxysmal nocturnal dyspnea, rales, elevated jugular venous pressure or S3, NYHA class, heart failure hospitalization in previous year, chronic respiratory disorder, 
baseline troponin, and body mass index.
‡For mg/dL divide by 88.4.
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had similar rates of worsening renal function (12.1% versus 
13.7%, P=0.265), although excluded patients more often died 
within 30 days (6.3% versus 3.2%, P<0.001).
Table 1 shows the baseline characteristics of the patient pop-
ulation in this study. In short, median age was 65±14 year, and 
34% were female. Nesiritide treatment was given to 50% of the 
included patients. A history of hypertension was present in 72% of 
patients, and 34% had a history of myocardial infarction. Median 
weight was 77 (64–94) kg with a median change in weight of 
−2.3 (−5.0 to −0.6) kg during hospitalization. Loop diuretics were 
administered in 89% of all patients within the first 24 hours.
Change in Renal Function
Median creatinine concentration increased from 1.2 (1.0–1.6) 
mg/dL at baseline to a maximum of 1.4 (1.1–1.8) mg/dL dur-
ing hospitalization. Median BUN concentration increased from 
25 (18–38) mmol/L at baseline to a maximum of 33 (23–50) 
mmol/L during hospitalization. The change from randomiza-
tion to hospital discharge in both serum creatinine and BUN 
was similar in nesiritide- and placebo-treated patients (P=0.20 
and P=0.41, respectively) as shown in Figure 1 and supported 
by the cumulative distribution curves shown in Figure 2.
As shown in Table 1, patients were split by those with a 
change in creatinine >0.3 mg/dL between baseline and peak. 
Patients with worsening renal function were older; more often 
female; and more often had diabetes mellitus, higher left ven-
tricular ejection fraction, higher baseline systolic blood pres-
sure, more cardiovascular comorbidities, a higher weight at 
baseline, and a larger decrease in weight during hospitalization.
Worsening renal function at any time from randomization 
through discharge occurred in 13.5% of the patients, and the 
frequency was similar in the nesiritide and placebo groups 
(14.1% and 12.8%, respectively; odds ratio [OR] with nesirit-
ide, 1.12; 95% confidence interval [CI], 0.95–1.32; P=0.19), 
regardless of the degree of baseline renal insufficiency (OR, 
1.01; 95% CI, 0.79–1.28; P=0.955 in patients with baseline 
estimated glomerular filtration rate <60 mL/min/1.73 m2, and 
OR, 1.24; 95% CI, 0.98–1.57; P=0.076 in patients with base-
line estimated glomerular filtration rate ≥60 mL/min/1.73 m2).
Using a multivariable stepwise model, we defined charac-
teristics that were related to changes in creatinine (Table 2). 
All prespecified factors included in the stepwise model are 
identified in Table 1 with a “†” symbol. In summary, a lower 
baseline BUN (log β = −0.091, P<0.0001), a higher systolic 
blood pressure (β = 0.002, P<0.0001), a lower diastolic blood 
pressure (β = −0.002, P<0.0001), a lower baseline potassium 
(β = −0.040, P<0.0001), and previous weight gain (β = 0.039, 
P<0.0001) were all significantly related to an increase in 
serum creatinine. Treatment with nesiritide did not have a sig-
nificant relation to a change in creatinine (β = 0.001, P=0.89).
Figure 2. Cumulative distribution curve. This figure displays the cumulative distribution curves of both nesiritide and placebo on (A) 
creatinine at end of treatment and (B) discharge/d 10.
Figure 1. Patients randomized to either nesiritide or placebo. This figure displays the changes in (A) serial creatinine levels and (B) BUN 
levels in patients randomized to either nesiritide or placebo. BUN indicates blood urea nitrogen.
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Predictive Value of Creatinine in Relation to 
Clinical Outcomes
The prognostic value of serum creatinine and change in serum 
creatinine at different time points is shown in Tables 3 and 4. 
In the subset of patients who had creatinine values measured at 
baseline and discharge, we found that both creatinine measures 
had strong associations with 30-day mortality (multivariable, 
P<0.001). Change in creatinine was also predictive of 30-day 
mortality (P<0.001; Table 3). In the set of patients with mea-
sures of both baseline and peak creatinine values, creatinines 
remained significant for 30-day mortality after adjusting for 
potential confounders, as did the change from baseline to peak 
(P=0.003, P=0.003, and P=0.01, respectively). The multivari-
able statistical significance of the evaluation of all creatinine 
values, updated across the hospitalization, was similar to that 
of the updated changes from baseline across time (P<0.001). 
Table 4 shows creatinine at discharge, peak, and across all val-
ues. All had strong associations with the combined end point 
of 30-day mortality or rehospitalization, even after adjusting 
for baseline covariates (P<0.001).
Discussion
In the present renal retrospective analysis of the ASCEND-HF 
trial, we found that nesiritide did not have any effect on 
changes in creatinine during hospitalization in patients with 
ADHF. By any point in time during hospitalization, renal 
function as measured by creatinine was associated with 
30-day death and 30-day death or rehospitalization including 
baseline, discharge, peak, change, or the most recent measure.
Worsening Renal Function
Renal dysfunction is prevalent in patients with both chronic 
and acute heart failure, and may influence patients’ treatments 
and outcomes.15,16 Approximately 20% to 40% of patients with 
acute heart failure have an increase in creatinine, which is gen-
erally defined as worsening renal function.15 We also found that 
the prevalence of diabetes mellitus was higher in patients with 
worsening renal function, which confirms previous studies.17,18
In our study, we found that baseline renal function was 
mildly impaired and further deteriorated during hospitaliza-
tion. Predictors of a decline in renal function (measured using 
creatinine on a continuous scale) included higher systolic and 
lower diastolic blood pressure, lower potassium levels, more 
previous weight gain, and lower BUN levels. Similar predic-
tors were found in previous studies.12,19–21
Nesiritide
In a meta-analysis of 5 randomized studies that included 1269 
ADHF patients, the frequency of worsening renal function 
was found to be 50% more prevalent in the nesiritide group.6 
Therefore, the neutral effects of nesiritide on renal function in 
the present study are markedly different from the meta-analysis. 
There are several potential explanations for this difference. First, 
in 3 of the 5 studies, detailed data could not be obtained because 
they have not been published.22 In the remaining 2 studies, 
nesiritide was not compared with placebo (as in ASCEND-HF), 
but was compared with either dobutamine23 or nitroglycerin3; 
we cannot exclude the possibility that these agents may have 
had a positive effect on renal function. Second, ASCEND-HF 
excluded patients with high risk of hypotension (systolic pressure 
<100 mm Hg or 110 mm Hg with the use of intravenous nitro-
glycerin), whereas the Vasodilation in the Management of Acute 
Congestive Heart Failure (VMAC) and Prospective Randomized 
Evaluation of Cardiac Ectopy with Dobutamine or Nesiritide 
Therapy (PRECEDENT) trials had less strict exclusion criteria 
for hypotension (90 mm Hg and 85 mm Hg, respectively). Finally, 
in the meta-analysis, the confidence intervals around the estimate 
were wide, suggesting that larger studies were needed. Also, pub-
lication of meta-analysis data from another study suggested that 
nesiritide might even improve renal function.23 Given the large 
sample size, ASCEND-HF had definitive power to demonstrate 
a meaningful difference in renal function between placebo and 
nesiritide, yet no difference was found.9
The present retrospective analysis of ASCEND-HF presents 
a more detailed report on the associations between nesiritide 
and other clinical predictors on changes in creatinine and 
BUN during hospitalization, as well as the drug’s association 
with clinical outcomes. We demonstrated that there was not a 
significant relationship between nesiritide and change in renal 
function when corrected for clinical characteristics and other 
laboratory measurements.
Table 2. Multivariable Model of Changes in Creatinine
Parameter 
Estimate
Standard 
Error P Value
Intercept 0.32977 0.05367 <0.0001
Randomization allocation* 0.00127 0.00939 0.8921
Log BUN −0.09123 0.00874 <0.0001
SBP measurement in standard units 0.00230 0.00028 <0.0001
Baseline DBP (mm Hg) −0.00183 0.00041 <0.0001
Baseline potassium (mmol/L) −0.04013 0.00818 <0.0001
Prior weight gain 0.03898 0.00992 <0.0001
BUN indicates blood urea nitrogen; DBP, diastolic blood pressure; and SBP, 
systolic blood pressure.
*Placebo is used as the reference group.
Table 3. Prognostic Value of Serum Creatinine for 30-Day 
Mortality
Univariable Multivariable
HR P Value HR P Value
Discharge creatinine n=4732 n=4290
Baseline* 1.62 <0.001 1.44 <0.001
Discharge* 1.82 <0.001 1.70 <0.001
Change† 1.31 <0.001 1.38 <0.001
Peak creatinine n=5607 n=5043
Baseline* 1.63 <0.001 1.40 0.003
Peak* 1.51 <0.001 1.37 0.003
Change† 1.09 0.0453 1.14 0.013
Time-dependent creatinine
Creatinine* 1.81 <0.001 1.7 <0.001
Change† 1.21 <0.001 1.2 <0.001
HR indicates hazard ratio.
*HR is for 1.5 increase in creatinine.
†HR is for 0.3 increase in change in creatinine.
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Because hypotension is related to worsening renal function in 
ADHF,24 there was some concern that patients with hypotension 
had a higher rate of renal impairment compared with those with-
out hypotension. We found this concern to be true in the overall 
group, as well as within each treatment group. Importantly, the 
overall relative risk of increased serum creatinine was the same 
within both treatment groups. So despite there being some cor-
relation between hypotension and renal dysfunction, there was 
no evidence of a stronger correlation when using nesiritide.
Outcomes
The conclusions on prognostic value of serum creatinine were 
drawn from the cohort of patients having baseline values, as 
well as ≥1 other creatinine values during hospitalization at any 
time. Importantly, we have also reported the results that were 
generated when ignoring creatinine values not being mea-
sured at discharge. Although the significance of the prognostic 
values may be attributable to ascertainment bias, we believe 
that in the setting of a randomized, clinical trial with standard-
ized measurement times of creatinine, it is more likely that 
the difference in P values is attributable to a different sample 
size of the 2 cohorts. We suggest measuring creatinine values 
more than once during hospitalization, for it is important to 
understand that the time of ascertainment of creatinine values 
can yield differences in the association with outcomes.
Both serum creatinine at baseline and serum creatinine at 
discharge had a strong association with both 30-day mortality 
and with the combined end point of 30-day mortality or rehos-
pitalization. Because change in renal function is a function of 
the baseline and discharge measures, it is not surprising that it, 
too, was also associated with short-term outcomes. Likewise, 
when examining the most recent measure of renal function, it 
is strongly associated with clinical outcomes.
A large number of studies reported an association between 
in-hospital worsening renal function and short-term out-
comes in patients with ADHF.11,12,25–32 However, others did not 
show such an association,33 perhaps because of patients hav-
ing a good diuretic response, developing a transient rise in 
creatinine, but having a good clinical outcome. In contrast, 
patients with a poor diuretic response and developing worsen-
ing renal function have a poor clinical outcome.
Differences in outcomes of studies relating worsening renal 
function in acute decompensated heart failure to outcome might 
also be caused by a measurement bias. Most studies do not mea-
sure creatinine routinely, so in those that did, there was probably 
a reason, which perhaps means that these patients were more 
likely to have worsening of symptoms or nonresponse to diuret-
ics34–36 related to clinical outcomes. This theory of measurement 
bias is supported by a recent study composed of 599 patients 
who had their serum creatinine levels routinely measured.32 The 
authors of this study concluded that worsening renal function 
is not an independent predictor of outcomes in patients with 
ADHF. Interestingly, they found that worsening renal function 
was prognostic in patients with persistent signs of congestion, 
suggesting a differential effect of worsening renal function. This 
may explain, at least to a degree, the strong significance noted 
in the models which used all creatinine measures updated over 
time compared with the model with discharge or peak only.
Limitations
Our study had several limitations. First, our study was a retro-
spective analysis. Second, our study has a possible selection 
bias inherent in clinical trial populations. For example, our 
population largely consisted of North American patients, pos-
sibly limiting the generalizability of our findings. Third, treat-
ment bias could have occurred because concurrent medication 
could have been altered as a result of changes in creatinine. 
Finally, 1439 patients did not have serial creatinine values 
during the inpatient stay, which could have potentially biased 
the finding that worsening renal function did not predict 
patient outcomes. For example, patients who lacked serial cre-
atinine values could have developed worsening renal function 
in-hospital and died before their serial creatinine was mea-
sured. Nevertheless, because of the design of ASCEND-HF, 
this study is more likely to have missing data because of less 
specific reasons, whereas other studies are more likely to have 
missing values because patients had no clinical suspicion to 
have worsening renal function or worse clinical outcomes.
Conclusions
In the present renal retrospective analysis of ASCEND-HF 
patients who were hospitalized with ADHF, nesiritide did 
not affect renal function. In addition, baseline, discharge, 
and change in renal dysfunction were associated with higher 
30-day mortality and rehospitalization for heart failure.
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CLINICAL PERSPECTIVE
Nesiritide is recombinant B-type natriuretic peptide approved for use in patients with acute heart failure, because of its ability 
to reduce pulmonary-capillary wedge pressure and improve dyspnea. Yet after its approval, it was suggested that nesiritide 
might cause renal toxicity and increase mortality. These concerns led to a marked decrease in the use of nesiritide. The Acute 
Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) was conducted to re-evaluate 
the efficacy and safety of nesiritide, compared with placebo, added to standard of care in 7141 acute decompensated heart 
failure (ADHF) patients. Overall, compared with placebo, nesiritide did not worsen clinical outcomes. In the present renal ret-
rospective analysis of the ASCEND-HF trial, we found that nesiritide did not have any effect on changes in creatinine during 
hospitalization in patients with ADHF. Furthermore, we examined the clinical predictors of changes in creatinine, and the rela-
tionship between changes in renal function and outcomes. At any time point during hospitalization, renal function as measured 
by creatinine was associated with 30-day death and 30-day death or rehospitalization including baseline, discharge, peak, 
change, or the most recent measure. We suggest measuring creatinine values more than once during hospitalization, for it is 
important to understand that the time of creatinine value ascertainment can yield differences in the association with outcomes.
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SUPPLEMENTAL MATERIAL 
 
Total number of patients reported in table 1, 3 and 4. 
 
Total number of patients reported in Table 1: 5702
     Death before discharge: 73
     Total number of baseline measurements equal to zero: 1
     Total number of peak values greater than or equal to ten: 9
     Total number of patients missing thirty day mortality status: 12
Total number of patients reported peak in Table 3: 5607
 
Total number of patients reported in Table 1: 5702
     Death before discharge: 73
     Total number of baseline measurements equal to zero: 1
     Total number of peak values greater than or equal to ten: 9
     Total number of patients missing thirty day mortality status: 152
Total number of patients reported peak in Table 4: 5467
 
Total number of patients reported baseline/DC values in Table 
3: 
4732
     Total number of patients missing thirty day mortality 
rehospitalization: 
90
Total number of patients reported baseline/DC values in Table 
4: 
4646
 
 
